Amgen Inc (AMGN) 158.88 $AMGN
Final Glance: Biotechnology companies
AP - 2 hrs 31 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
Stocks Trim Losses After Fed Report; Solarwinds Soars
at Investor's Business Daily - Wed Oct 29, 3:22PM CDT
Stocks trimmed losses but couldn't avoid a heavy volume decline Wednesday. The Nasdaq fell 0.3%, the S&P 500 dropped 0.2% and the Dow Jones industrial average fell 0.1%. Preliminary numbers showed volume was higher across the board in the stock...
SWI: 47.25 (+4.67), AFSI: 46.04 (-6.99), AMGN: 158.88 (+1.69), SCOR: 40.44 (+1.69)
Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:05PM CDT
Amgen (AMGN) provided a comprehensive review of its strategic plans, growth objectives and capital allocation in a business review meeting.
MDVN: 99.55 (-1.63), BIIB: 315.06 (-2.97), ILMN: 188.88 (-1.77), AMGN: 158.88 (+1.69)
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 315.06 (-2.97), LGND: 53.33 (+1.44), AMGN: 158.88 (+1.69), GSK: 45.08 (-0.02)
Midday Glance: Biotechnology companies
AP - Wed Oct 29, 12:41PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 315.06 (-2.97), CBST: 71.35 (-0.99), MDCO: 25.16 (-0.70), SRPT: 15.19 (+0.07), ALXN: 190.49 (-1.71), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 65.65 (-0.93), VRX: 129.76 (-1.31), ACT: 238.78 (-0.25), AMGN: 158.88 (+1.69), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), AGN: 186.77 (+4.17), JNJ: 105.56 (+0.77), SHPG: 196.45 (-1.35), MRK: 56.20 (+0.35), INFI: 13.58 (-0.08), ABBV: 59.98 (-0.95), KPTI: 39.81 (+1.78)
Early Glance: Biotechnology companies
AP - Wed Oct 29, 9:53AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
Stock Market News for October 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 9:10AM CDT
Benchmarks advanced significantly on Tuesday, banking on positive earnings results and upbeat consumer confidence data
KSS: 54.44 (-0.22), HON: 95.05 (-0.12), PFE: 29.49 (+0.40), HAL: 54.42 (+1.16), AMGN: 158.88 (+1.69), XOM: 94.59 (-0.51), CSX: 35.40 (+0.11), AET: 79.75 (+2.52), SLB: 97.41 (+0.90), COH: 33.80 (-0.20), CMI: 144.51 (-0.08), CHK: 21.59 (-0.01), EOG: 93.13 (+1.63), TWTR: 42.08 (-1.70), CVX: 117.14 (+0.01), AN: 55.76 (+0.18)
Upgrade Alert for Amgen (AMGN)
Comtex SmarTrend(R) - Wed Oct 29, 6:56AM CDT
Amgen (NASDAQ:AMGN) was upgraded from Neutral to Buy at Nomura today. The stock closed yesterday at $157.19 on volume of 11.5 million shares, above average daily volume of 4.1 million. Amgen (NASDAQ:AMGN) defies analysts with a current price ($157.19) 7.1% above its average consensus price target of $146.05. The stock should find initial support at its 50-day moving average (MA) of $138.41 and further support at its 200-day MA of $124.33.
AMGN: 158.88 (+1.69)
Pfizer Inc.'s Earnings: Emerging Market Growth and Patent Expirations Square Off
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 29, 5:49AM CDT
Source: Flickr user David Goehring. Big pharmaceutical companies are in the midst of dealing with the most sweeping patent cliff in their history, and Pfizer is still dangling on the edge. Having lost Lipitor, Viagra, and a number of other...
PFE: 29.49 (+0.40), AMGN: 158.88 (+1.69), NVS: 91.31 (-1.04)
Asian stocks rise with Wall Street, eyes on Fed
By YURI KAGEYAMA - AP - Tue Oct 28, 10:02PM CDT
TOKYO (AP) — Asian stocks swung upward early Wednesday, cheered by a surge in U.S. stocks buoyed by solid earnings, but investors were also waiting for signs from the Federal Reserve on U.S. monetary policy.
MSG: 74.72 (+1.73), AMGN: 158.88 (+1.69), WFC: 52.17 (+0.39)
Amgen resists pressure to split
at Investor's Business Daily - Tue Oct 28, 5:43PM CDT
The drug giant offered '15 revenue guidance of $20.8 bil-$21.3 bil, above consensus of $20.4 bil. And it guided EPS to $9.05-$9.40, topping views for $9. On Tue., Amgen announced an additional 5% head-count reduction that, with cuts announced last...
AMGN: 158.88 (+1.69)
Market News: Amgen, Inc., The Madison Square Garden Co, Twitter Inc
at The Street - Tue Oct 28, 3:48PM CDT
Economists expected policy makers to maintain low interests rates for a considerable timeThe stock markets in the United States rallied today as investors evaluate data and corporate earnings prior to...
MSG: 74.72 (+1.73), AMGN: 158.88 (+1.69), TWTR: 42.08 (-1.70)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.11 (-0.22), KSS: 54.44 (-0.22), MU: 32.28 (-0.33), PFE: 29.49 (+0.40), HAL: 54.42 (+1.16), AMGN: 158.88 (+1.69), NQ: 7.81 (-0.19), RGC: 21.64 (+0.36), MS: 34.39 (+0.03), MSG: 74.72 (+1.73), NVAX: 5.41 (-0.07), CQB: 14.39 (unch), SRPT: 15.19 (+0.07), RCPT: 98.30 (+2.54), TWTR: 42.08 (-1.70), PTIE: 1.99 (-0.08)
Amgen Set to Possibly Pullback After Yesterday's Rally of 6.07%
Comtex SmarTrend(R) - Tue Oct 28, 3:40PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.47 to a high of $157.25. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $148.47 on volume of 11.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 158.88 (+1.69)
After Yesterday's Rally of 6.07% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Oct 28, 3:40PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.47 to a high of $157.25. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $148.47 on volume of 11.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 158.88 (+1.69)
Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease
PR Newswire - Tue Oct 28, 3:00PM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has regained all development and commercial rights to XmAb®5871 by seeking and obtaining a termination of the prior option and collaboration agreement and executing a new right-of-first-negotiation agreement with Amgen. XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary immune inhibitor XmAb Fc domain that targets FcRIIb to inhibit B-cell function. XmAb5871 is currently in a Phase 1b/2a clinical trial in patients with moderate-to-severe rheumatoid arthritis (RA) and topline results are expected by the end of 2014. The company is planning clinical development in multiple autoimmune diseases where B-cell inhibition shows promise, including IgG4-related disease.
AMGN: 158.88 (+1.69), XNCR: 10.49 (-0.11)
Amgen Refuses To Split, But Plans Hearten Investors
at Investor's Business Daily - Tue Oct 28, 1:18PM CDT
Big-cap biotech Amgen (AMGN) offered 2015 guidance, set 2018 targets and resisted pressure to split at a business-review meeting Tuesday. On the heels of Monday's Q3 earnings beat, Amgen's action helped drive the stock up more than 5% in afternoon...
AMGN: 158.88 (+1.69), ABBV: 59.98 (-0.95)
Final Glance: Biotechnology companies
AP - 2 hrs 31 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
Stocks Trim Losses After Fed Report; Solarwinds Soars
at Investor's Business Daily - Wed Oct 29, 3:22PM CDT
Stocks trimmed losses but couldn't avoid a heavy volume decline Wednesday. The Nasdaq fell 0.3%, the S&P 500 dropped 0.2% and the Dow Jones industrial average fell 0.1%. Preliminary numbers showed volume was higher across the board in the stock...
SWI: 47.25 (+4.67), AFSI: 46.04 (-6.99), AMGN: 158.88 (+1.69), SCOR: 40.44 (+1.69)
Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:05PM CDT
Amgen (AMGN) provided a comprehensive review of its strategic plans, growth objectives and capital allocation in a business review meeting.
MDVN: 99.55 (-1.63), BIIB: 315.06 (-2.97), ILMN: 188.88 (-1.77), AMGN: 158.88 (+1.69)
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 315.06 (-2.97), LGND: 53.33 (+1.44), AMGN: 158.88 (+1.69), GSK: 45.08 (-0.02)
Midday Glance: Biotechnology companies
AP - Wed Oct 29, 12:41PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 315.06 (-2.97), CBST: 71.35 (-0.99), MDCO: 25.16 (-0.70), SRPT: 15.19 (+0.07), ALXN: 190.49 (-1.71), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 65.65 (-0.93), VRX: 129.76 (-1.31), ACT: 238.78 (-0.25), AMGN: 158.88 (+1.69), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), AGN: 186.77 (+4.17), JNJ: 105.56 (+0.77), SHPG: 196.45 (-1.35), MRK: 56.20 (+0.35), INFI: 13.58 (-0.08), ABBV: 59.98 (-0.95), KPTI: 39.81 (+1.78)
Early Glance: Biotechnology companies
AP - Wed Oct 29, 9:53AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)
Stock Market News for October 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 9:10AM CDT
Benchmarks advanced significantly on Tuesday, banking on positive earnings results and upbeat consumer confidence data
KSS: 54.44 (-0.22), HON: 95.05 (-0.12), PFE: 29.49 (+0.40), HAL: 54.42 (+1.16), AMGN: 158.88 (+1.69), XOM: 94.59 (-0.51), CSX: 35.40 (+0.11), AET: 79.75 (+2.52), SLB: 97.41 (+0.90), COH: 33.80 (-0.20), CMI: 144.51 (-0.08), CHK: 21.59 (-0.01), EOG: 93.13 (+1.63), TWTR: 42.08 (-1.70), CVX: 117.14 (+0.01), AN: 55.76 (+0.18)
Upgrade Alert for Amgen (AMGN)
Comtex SmarTrend(R) - Wed Oct 29, 6:56AM CDT
Amgen (NASDAQ:AMGN) was upgraded from Neutral to Buy at Nomura today. The stock closed yesterday at $157.19 on volume of 11.5 million shares, above average daily volume of 4.1 million. Amgen (NASDAQ:AMGN) defies analysts with a current price ($157.19) 7.1% above its average consensus price target of $146.05. The stock should find initial support at its 50-day moving average (MA) of $138.41 and further support at its 200-day MA of $124.33.
AMGN: 158.88 (+1.69)
Pfizer Inc.'s Earnings: Emerging Market Growth and Patent Expirations Square Off
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 29, 5:49AM CDT
Source: Flickr user David Goehring. Big pharmaceutical companies are in the midst of dealing with the most sweeping patent cliff in their history, and Pfizer is still dangling on the edge. Having lost Lipitor, Viagra, and a number of other...
PFE: 29.49 (+0.40), AMGN: 158.88 (+1.69), NVS: 91.31 (-1.04)
Asian stocks rise with Wall Street, eyes on Fed
By YURI KAGEYAMA - AP - Tue Oct 28, 10:02PM CDT
TOKYO (AP) — Asian stocks swung upward early Wednesday, cheered by a surge in U.S. stocks buoyed by solid earnings, but investors were also waiting for signs from the Federal Reserve on U.S. monetary policy.
MSG: 74.72 (+1.73), AMGN: 158.88 (+1.69), WFC: 52.17 (+0.39)
Amgen resists pressure to split
at Investor's Business Daily - Tue Oct 28, 5:43PM CDT
The drug giant offered '15 revenue guidance of $20.8 bil-$21.3 bil, above consensus of $20.4 bil. And it guided EPS to $9.05-$9.40, topping views for $9. On Tue., Amgen announced an additional 5% head-count reduction that, with cuts announced last...
AMGN: 158.88 (+1.69)
Market News: Amgen, Inc., The Madison Square Garden Co, Twitter Inc
at The Street - Tue Oct 28, 3:48PM CDT
Economists expected policy makers to maintain low interests rates for a considerable timeThe stock markets in the United States rallied today as investors evaluate data and corporate earnings prior to...
MSG: 74.72 (+1.73), AMGN: 158.88 (+1.69), TWTR: 42.08 (-1.70)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.11 (-0.22), KSS: 54.44 (-0.22), MU: 32.28 (-0.33), PFE: 29.49 (+0.40), HAL: 54.42 (+1.16), AMGN: 158.88 (+1.69), NQ: 7.81 (-0.19), RGC: 21.64 (+0.36), MS: 34.39 (+0.03), MSG: 74.72 (+1.73), NVAX: 5.41 (-0.07), CQB: 14.39 (unch), SRPT: 15.19 (+0.07), RCPT: 98.30 (+2.54), TWTR: 42.08 (-1.70), PTIE: 1.99 (-0.08)
Amgen Set to Possibly Pullback After Yesterday's Rally of 6.07%
Comtex SmarTrend(R) - Tue Oct 28, 3:40PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.47 to a high of $157.25. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $148.47 on volume of 11.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 158.88 (+1.69)
After Yesterday's Rally of 6.07% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Oct 28, 3:40PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.47 to a high of $157.25. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $148.47 on volume of 11.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 158.88 (+1.69)
Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease
PR Newswire - Tue Oct 28, 3:00PM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has regained all development and commercial rights to XmAb®5871 by seeking and obtaining a termination of the prior option and collaboration agreement and executing a new right-of-first-negotiation agreement with Amgen. XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary immune inhibitor XmAb Fc domain that targets FcRIIb to inhibit B-cell function. XmAb5871 is currently in a Phase 1b/2a clinical trial in patients with moderate-to-severe rheumatoid arthritis (RA) and topline results are expected by the end of 2014. The company is planning clinical development in multiple autoimmune diseases where B-cell inhibition shows promise, including IgG4-related disease.
AMGN: 158.88 (+1.69), XNCR: 10.49 (-0.11)
Amgen Refuses To Split, But Plans Hearten Investors
at Investor's Business Daily - Tue Oct 28, 1:18PM CDT
Big-cap biotech Amgen (AMGN) offered 2015 guidance, set 2018 targets and resisted pressure to split at a business-review meeting Tuesday. On the heels of Monday's Q3 earnings beat, Amgen's action helped drive the stock up more than 5% in afternoon...
AMGN: 158.88 (+1.69), ABBV: 59.98 (-0.95)
